JAK3 and primary cutaneous T-cell non-Hodgkin lymphoma: Our results suggest that JAK3-INSL3 fusion may contribute to constituting the activation of the JAK/STAT pathway in CTCL and support the therapeutic targeting of the JAK/STAT pathway.